Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | NCF1 | P14598 | 3/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.55 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.54 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NOS3 | P29474 | 3/20 | 0.51 |
| ▸ | NOS1 | P29475 | 3/20 | 0.51 |
| ▸ | NOS2 | P35228 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89010 | 0.78 | CYP1A2 (1.00) | BACE1CYP1A2NCF1NPFFR1NPFFR2 | |
| SCHEMBL1088580 | 0.78 | CYP1A2 (0.69) | BACE1CYP1A2NCF1NPFFR1NPFFR2 | |
| SCHEMBL29690490 | 0.78 | NCF1 (0.64) | BACE1NCF1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL29502790 | 0.78 | CYP1A2 (1.00) | BACE1CYP1A2NCF1NPFFR1NPFFR2 | |
| SCHEMBL323374 | 0.78 | NCF1 (0.64) | BACE1NCF1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL9724255 | 0.78 | BACE1 (0.63) | BACE1PRMT5SMN1; SMN2RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL11674460 | 0.77 | CYP1A2 (0.96) | BACE1CYP1A2NCF1NPFFR1NPFFR2 | |
| SCHEMBL26695128 | 0.76 | BACE1 (0.61) | BACE1CYP1A2NCF1SMN1; SMN2RAB9A | |
| SCHEMBL7050208 | 0.76 | BACE1 (0.61) | BACE1CYP1A2NCF1SMN1; SMN2RAB9A | |
| SCHEMBL31667822 | 0.75 | BACE1 (0.60) | BACE1CYP1A2NCF1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771456-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | Palumed SA (FR) | 2007-04-11 | — | — | EP | claimed |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | PALUMED S.A. (FR) | 2007-03-15 | — | — | US | claimed |
| WO-2006024741-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | PALUMED S.A. (FR) | 2006-03-09 | — | — | WO | claimed |
| WO-2003013523-A1 | SH3 PROTEIN DOMAINS AND THEIR LIGANDS | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2003-02-20 | — | — | WO | claimed |
| CN-115867277-A | Novel fused heterocyclyl-carbohydrazone acyldinitrile compounds and use thereof | 韩国科学技术研究院 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023040998-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022076629-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021239058-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-12-02 | — | — | WO | disclosed |
| CN-113651820-A | Urea compounds for dual IDO and TDO inhibitors | 正大天晴药业集团股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-3326715-B1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | CE PHARM CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-110382500-B | Urea compounds for dual IDO and TDO inhibitors | 正大天晴药业集团股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| WO-2021105497-A1 | SMALL-MOLECULE NADPH OXIDASE 2 INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2021-06-03 | — | — | WO | disclosed |
| WO-2003013523-A1 | SH3 PROTEIN DOMAINS AND THEIR LIGANDS | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2003-02-20 | — | — | WO | disclosed |
| EP-0587499-B1 | Benzopyran compounds, process for their preparation and their use as cell protectors | ADIR (FR) | 1998-04-29 | — | — | EP | disclosed |
| US-5395834-A | Antiarthritic agents or cardiovascular disorders | ADIR ET COMPAGNIE (FR) | 1995-03-07 | — | — | US | disclosed |
| US-5393775-A | Administering a (2-chromanyl)alkylcarboxylic acid for disorders connected with peroxidation processes | ADIR ET COMPAGNIE (FR) | 1995-02-28 | — | — | US | disclosed |
| US-5315017-A | Peroxidation and eicosanoid biosynthesis inhibition | ADIR ET COMPAGNIE (FR) | 1994-05-24 | — | — | US | disclosed |
| EP-0587499-A1 | Benzopyran compounds, process for their preparation and their use as cell protectors | ADIR ET COMPAGNIE (FR) | 1994-03-16 | — | — | EP | disclosed |
| EP-0512899-A1 | Benzopyran compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-11-11 | — | — | EP | disclosed |
| CN-87102669-A | Fiberboard and manufacture method thereof | — | 1987-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | QARS1, QPCT, QTRT2 | BACE1 3067/4885CYP1A2 284/4885NCF1 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.